Penumbra Q2 revenue up 13.4%, beats estimates

Penumbra

29/07/2025 21:17

Overview

Penumbra Q2 2025 revenue rises 13.4% yr/yr, beating analyst expectations

U.S. thrombectomy revenue increases 22.6%, driving overall revenue growth

Net income for Q2 2025 reaches $45.3 mln, adjusted EBITDA at $61.4 mln

Outlook

Penumbra raises 2025 revenue guidance to $1.355 bln-$1.370 bln

Company maintains U.S. Thrombectomy growth guidance at 20%-21%

Penumbra maintains guidance for both gross margin and operating margin for full year 2025

Company anticipates sequential gross margin expansion in H2 2025

Result Drivers

U.S. THROMBECTOMY - Revenue from U.S. thrombectomy products increased by 22.6%, driving overall revenue growth

PRODUCT MIX - Favorable product mix and productivity improvements contributed to higher gross margin

INTERNATIONAL CHALLENGES - International revenue decreased by 3.2%, highlighting regional challenges

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$339.46 mln
$327.70 mln (18 Analysts)
Q2 Net Income
$45.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Penumbra Inc is $320.00, about 28.1% above its July 28 closing price of $230.17

The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 67 three months ago

Press Release: ID:nPn1nhsXFa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)